Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: phosphatidylcholine-complexed therapeutics - PLx

Drug Profile

Research programme: phosphatidylcholine-complexed therapeutics - PLx

Alternative Names: Indometacin/phosphatidylcholine; Indomethacin-PC; Indomethacin/phosphatidylcholine; Ketorolac/phosphatidylcholine; Meloxicam/phosphatidylcholine; Mesalazine (PL9100 5-ASA); Piroxicam-PC; Piroxicam/phosphatidylcholine; PL 4100; PL 4500; PL 9100 5-ASA

Latest Information Update: 28 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PLx Pharma
  • Class
  • Mechanism of Action Cyclooxygenase inhibitors; Lipoxygenase-cyclooxygenase inhibitors; Prostaglandin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Congenital heart defects
  • Discontinued Gout; Inflammation; Pain; Ulcerative colitis

Most Recent Events

  • 28 Oct 2018 No recent reports of development identified for preclinical development in Congenital-heart-disorders in USA (IV)
  • 20 Oct 2017 Discontinued - Preclinical for Ulcerative colitis, Pain, Inflammation and Gout (PO), and Pain (IV) in USA (PLx Pharma pipeline, October 2017)
  • 24 Oct 2016 Indomethacin (PL 4100) is still in preclinical development for Congenital-heart-disorders and pain in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top